¼¼°èÀÇ ÇǺΠÀç»ý ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)
Dermal Regeneration Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1773272
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 140 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,831,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,521,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,760,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ÇǺΠÀç»ý ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 10¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, CAGR 7.7%·Î ¼ºÀåÇÏ¿© 2034³â¿¡´Â 21¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ·¯ÇÑ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº ºñħ½ÀÀû ¹Ì¿ë Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, È­»ó, ´ç´¢º´¼º Á·ºÎ±Ë¾ç, Á¤¸Æ¼º ÇÏÁö±Ë¾ç, ¿åâ°ú °°Àº ¸¸¼º »óóÀÇ ³ôÀº À¯º´·üÀ» µé ¼ö ÀÖ½À´Ï´Ù. ´ç´¢º´ Àα¸ Áõ°¡¿Í Àü ¼¼°èÀûÀÎ °í·ÉÈ­·Î ÀÎÇØ ÀÌ·¯ÇÑ ÁúȯÀÌ ´õ¿í ÈçÇØÁö¸é¼­ °í±Þ »óó Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÑ »óó Áõ°¡·Î ÀÎÇØ ÷´Ü ÇǺΠÀç»ý ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.

?ù«î¢ßæMarket-IMG1

¶ÇÇÑ, ¹ÙÀÌ¿À ¿£Áö´Ï¾î¸µÀ» ÅëÇÑ ´ëü ÇǺÎ, ½ºÄ³Æúµå, ¼ºÀåÀÎÀÚ Ä¡·á¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ ¹ßÀüÀº ½ÃÀåÀÇ Ãß°¡ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÇコÄɾî ÀÚ±Ý Áõ°¡, ÷´Ü Ä¡·á È¿°ú¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áö¿øÀûÀÎ »óȯ Á¤Ã¥Àº ¸ðµÎ ÇǺΠÀç»ý Á¦Ç°¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä¸¦ À¯ÁöÇÏ°í °¡¼ÓÈ­ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
°³½Ã ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
°³½Ã ±Ý¾× 10¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ±Ý¾× 21¾ï ´Þ·¯
CAGR 7.7%

ÇǺΠÀç»ýÀº ÁøÇÇ ´ëü¹°, ½ºÄ³Æúµå, ¼¼Æ÷¼º ¶Ç´Â ¼¼Æ÷¼º ¸ÅÆ®¸¯½º¿Í °°Àº ´Ù¾çÇÑ Á¢±Ù¹ýÀ» »ç¿ëÇÏ¿© ÇǺÎÀÇ ¿ÏÀü¼ºÀ» ȸº¹Çϵµ·Ï ¼³°èµÈ Àç°Ç °úÁ¤À» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ Á¦Ç°µéÀº Á¶Á÷ ÅëÇÕ, Ç÷¾× ¼øÈ¯ Àç°Ç, È¿°úÀûÀÎ »óó ºÀÇÕÀ» ÃËÁøÇÏ¿© ¸¸¼º »óó, È­»ó, ¿Ü»ó, Àç°Ç ¼ö¼úÀÇ Ä¡À¯¸¦ µ½±â À§ÇØ Æ¯º°È÷ °í¾ÈµÈ Á¦Ç°ÀÔ´Ï´Ù.

2024³â ÇǺΠ´ëüÀç ºÎ¹®Àº 5¾ï 9,730¸¸ ´Þ·¯ ±Ô¸ð·Î ½ÃÀåÀ» ÁÖµµÇßÀ¸¸ç, 2034³â±îÁö ¿¬Æò±Õ 7.5%ÀÇ ¼ºÀå·ü·Î 12¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â ÇÕ¼º ¹× »ý¹°ÇÐÀû ÇǺΠ´ëü¹°ÀÌ Æ÷ÇԵ˴ϴÙ. ¸¸¼º »óó, È­»ó, ¿Ü°úÀû »óó °ü¸®¿¡ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÇ¾î ±âÁ¸ ÀÌ½ÄÆí¿¡ ºñÇØ °¨¿° À§Çè°ú ÈäÅÍ Çü¼ºÀ» °¨¼Ò½Ã۰í Ä¡À¯ °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÇǺΠ´ëüÀç´Â ´ç´¢º´¼º Á·ºÎ ±Ë¾çÀ̳ª ±¤¹üÀ§ÇÑ È­»ó µî º¹ÀâÇÑ ÁúȯÀÇ Ä¡·á¿¡ È¿°úÀûÀ̱⠶§¹®¿¡ ÀÓ»óÀǵéÀÌ ¼±È£Çϰí ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº FDA ½ÂÀÎ Áõ°¡, °­·ÂÇÑ ÀÓ»óÀû Áõ°Å, ƯÈ÷ ¼±Áø±¹¿¡¼­ È®¸³µÈ »óȯ ÇÁ·¹ÀÓ¿öÅ©¿¡ ÀÇÇØ ´õ¿í µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù.

¸¸¼º »óó ºÎ¹®Àº 2024³â 39.5%ÀÇ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â ´ç´¢º´¼º Á·ºÎ ±Ë¾ç, Á¤¸Æ¼º ÇÏÁö ±Ë¾ç, ¿åâ µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀüÅëÀûÀÎ »óó Ä¡·á¹ýÀº ƯÈ÷ ´ç´¢º´ ȯÀÚ¿¡¼­ Á¾Á¾ ¹®Á¦°¡ ¹ß»ýÇϱ⠶§¹®¿¡ Çõ½ÅÀûÀÎ ´ëü ÇǺΠ¹× Àç»ý Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¸¼º »óó Ä¡·á´Â Àå±âÀûÀ̰í Á¾ÇÕÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇϸç, ÀÌ´Â ÀÇ·á ºñ¿ë°ú ȯÀÚÀÇ »îÀÇ Áú¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. µû¶ó¼­ ÷´Ü ÇǺΠÀç»ý Á¦Ç°Àº ´õ ³ªÀº Ä¡·á °á°ú¸¦ °¡Á®¿À°í ÀÔ¿ø ±â°£°ú ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ ÇǺΠÀç»ý ½ÃÀåÀº 2024³â 4¾ï 4,000¸¸ ´Þ·¯ ±Ô¸ð·Î Æò°¡µÇ¾ú°í, 2025-2034³â ¿¬Æò±Õ 7.2%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹Ì±¹Àº ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ¸¸¼º »óó ¹ß»ý·ü, Àç»ýÀÇ·á ¿¬±¸¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î ¼±µµÀûÀÎ À§Ä¡¸¦ À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº ÷´Ü »ýÇÕ¼º ¸ÅÆ®¸¯½º, ¼¼Æ÷Ä¡·á, ½ºÄ³Æúµå(scaffold)¸¦ ±¤¹üÀ§ÇÏ°Ô Ã¤ÅÃÇϰí ÀÖÀ¸¸ç, FDA ½ÂÀÎÀ» ¹ÞÀº Ư¼ö ÇǺΠ´ëüÀç¿Í °°Àº Çõ½ÅÀûÀÎ Á¦Ç°µéÀÌ ½ÃÀå ¼ºÀå¼¼¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ÇǺΠÀç»ý »ê¾÷ÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â MiMedx,Integra LifeSciences,Avita Medical,Gunze,Smith &Nephew,Organogenesis,PolyNovo,RTI Surgical,BioTissue,Extremity Care,Kerecis(Coloplast),MedSkin Solutions Dr. Suwelack,Stryker,Zimmer Biomet,Tissue Regenix µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ±â¾÷µéÀº ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ º¹ÀâÇÑ »óó À¯Çü¿¡ ¸ÂÃß¾î º¸´Ù È¿°úÀûÀÌ°í »ýüÀûÇÕ¼ºÀÌ ³ôÀ¸¸ç »ç¿ëÇϱ⠽¬¿î Á¦Ç°ÀÇ ¿¬±¸°³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº ±â¾÷µéÀÌ ÅëÇÕ¼º°ú Ä¡À¯ Ư¼ºÀ» °³¼±ÇÑ Â÷¼¼´ë ÇǺΠ´ëüÀç ¹× ½ºÄ³Æúµå ±â¼ú °³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ¹× ¿¬±¸ ±â°ü°úÀÇ Àü·«Àû Á¦ÈÞ ¹× ÆÄÆ®³Ê½ÊÀ» ÅëÇØ º¸´Ù ºü¸¥ ÀÓ»ó µµÀÔ°ú Áö¸®Àû È®ÀåÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ ½ÃÀå ÁøÀÔÀ» º¸ÀåÇϱâ À§ÇØ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú »óȯ Çù»óÀ» ¿ì¼±¼øÀ§¿¡ µÎ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Ç° À¯Çüº°, 2021-2034³â

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¿ëµµº°, 2021-2034³â

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2034³â

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2034³â

Á¦9Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Dermal Regeneration Market was valued at USD 1.01 billion in 2024 and is estimated to grow at a CAGR of 7.7% to reach USD 2.1 billion by 2034. This expansion is mainly fueled by the increasing demand for non-invasive cosmetic treatments, a rising number of burn injuries, and the high prevalence of chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. These conditions are becoming more common due to the growing diabetic population and the aging demographic worldwide, driving the need for advanced wound care therapies. The rising incidence of these complicated wounds creates a pressing demand for sophisticated dermal regeneration solutions.

Dermal Regeneration Market - IMG1

Moreover, the advancement of innovative treatment options, including bioengineered skin substitutes, scaffolds, and growth factor-based therapies, supports further market growth. Increased healthcare funding, growing awareness of advanced treatment benefits, and supportive reimbursement policies all contribute to sustaining and accelerating demand for dermal regeneration products globally.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.01 Billion
Forecast Value$2.1 Billion
CAGR7.7%

Dermal regeneration involves reconstructive processes designed to restore skin integrity using various approaches such as dermal substitutes, scaffolds, and cellular, or acellular matrices. These products are specifically engineered to aid in healing chronic wounds, burns, traumatic injuries, and reconstructive surgeries by promoting tissue integration, revascularization, and effective wound closure.

In 2024, the skin substitutes segment led the market with a valuation of USD 597.3 million and is expected to reach USD 1.2 billion by 2034, growing at a CAGR of 7.5%. This segment comprises both synthetic and biological skin substitutes. Their broad application in managing chronic wounds, burns, and surgical wounds enhances healing outcomes by reducing infection risk and scarring compared to conventional grafts. Clinicians favor these substitutes for their effectiveness in treating complex conditions like diabetic foot ulcers and extensive burn injuries. The segment's growth is further supported by increasing FDA approvals, strong clinical evidence, and well-established reimbursement frameworks, especially in developed regions.

The chronic wounds segment captured the largest market share of 39.5% in 2024 and is forecasted to maintain strong growth throughout the forecast period. This segment includes diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Traditional wound healing methods often face challenges, particularly in diabetic patients, which escalates the demand for innovative skin substitutes and regenerative therapies. Managing chronic wounds requires prolonged and comprehensive care, significantly affecting healthcare costs and patient quality of life. Consequently, advanced dermal regeneration products offer better therapeutic outcomes, reducing hospitalization time and complications.

U.S. Dermal Regeneration Market generated USD 404 million in 2024 and is anticipated to grow at a CAGR of 7.2% from 2025 through 2034. The U.S. maintains its leadership position due to its advanced healthcare infrastructure, high rates of chronic wound incidence, and substantial investments in regenerative medicine research. The country widely adopts sophisticated biosynthetic matrices, cellular therapies, and scaffolds, making it a global front-runner in dermal regeneration. Innovative products like specialized skin substitutes with FDA clearance are propelling market momentum.

Leading companies in the Dermal Regeneration Industry include MiMedx, Integra LifeSciences, Avita Medical, Gunze, Smith & Nephew, Organogenesis, PolyNovo, RTI Surgical, BioTissue, Extremity Care, Kerecis (Coloplast), MedSkin Solutions Dr. Suwelack, Stryker, Zimmer Biomet, and Tissue Regenix. To solidify their market presence, companies in the dermal regeneration sector are focusing heavily on research and development to innovate more effective, biocompatible, and easy-to-use products tailored to complex wound types. Many are investing in developing next-generation skin substitutes and scaffold technologies with improved integration and healing properties. Strategic collaborations and partnerships with healthcare providers and research institutions enable faster clinical adoption and expanded geographic reach. Firms also prioritize regulatory approvals and reimbursement negotiations to ensure market access.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â